Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 331-340 of 639 results
Frontiers in Pharmacology, 2016 • March 8, 2016
This study investigated the neuroregenerative properties of co-ultraPEALut in a murine model of spinal cord injury (SCI). The findings demonstrated that co-ultraPEALut treatment increased cell prolife...
KEY FINDING: Co-ultraPEALut increased the numbers of both bromodeoxyuridine-positive nuclei and doublecortin-immunoreactive cells in the spinal cord of injured mice, indicating increased cell proliferation and neurogenesis.
International Journal of Clinical Pharmacy, 2021 • October 9, 2020
The study investigated the potential of montelukast, a leukotriene receptor antagonist, to alleviate age-related neurological decline using Norwegian registry data. The results suggested that previous...
KEY FINDING: Previous use of montelukast correlated with improved scores on cognitive or neurological functioning.
Neural Regeneration Research, 2021 • January 7, 2021
This research investigates the potential of ISP and PAP4 peptides to promote motor functional recovery following peripheral nerve injury, specifically brachial plexus injury, in a rat model. The study...
KEY FINDING: ISP and PAP4 treatments significantly increased the survival of motoneurons in rats with brachial plexus injury.
The Journal of Spinal Cord Medicine, 2017 • March 1, 2017
This study highlights the high incidence of polypharmacy among individuals with spinal cord injury (SCI) and the associated increased risk of drug-related problems (DRPs). A significant percentage of ...
KEY FINDING: Patients with SCI were prescribed significantly more medications than their counterparts without SCI.
JOURNAL OF NEUROTRAUMA, 2014 • August 1, 2014
This study evaluated the acute effects of serotonergic medications on locomotor performance in individuals with incomplete spinal cord injury (iSCI). The study found that administration of a 5HT antag...
KEY FINDING: Neither SSRIs nor 5HT antagonists improved locomotion in iSCI subjects.
The Journal of Spinal Cord Medicine, 2015 • January 1, 2015
This retrospective study investigated the protective effect of oral alendronate (ALN) intake on the appearance of heterotopic ossification (HO) in patients with spinal cord injury (SCI). The study fou...
KEY FINDING: There was no statistically significant difference in the incidence of HO in patients receiving oral ALN compared to those not receiving it.
Annals of Rehabilitation Medicine, 2014 • August 1, 2014
This study investigated the effects of early tamsulosin treatment on bladder function in a spinal cord injury rat model. Researchers measured bladder pressures, contractility, and protein expression l...
KEY FINDING: Tamsulosin treatment decreased acetylcholine-induced bladder contraction in rats with spinal cord injury.
Journal of Pain Research, 2014 • July 28, 2014
The study aimed to evaluate the long-term safety and tolerability of pregabalin in Japanese patients with central neuropathic pain over a 53-week period. The results indicated that pregabalin was gene...
KEY FINDING: A majority of patients (87.4%) experienced at least one treatment-related adverse event, most commonly somnolence, weight gain, dizziness, or peripheral edema.
Acta Biomater., 2015 • January 1, 2015
The study assessed the biocompatibility of a coacervate-based drug delivery system in damaged nervous tissue using a rat model of contusive SCI, focusing on the effects of heparin and PEAD on inflamma...
KEY FINDING: The [PEAD:heparin] coacervate did not exacerbate inflammation, glial scarring, or nervous tissue loss, which are hallmarks of spinal cord injury.
The Journal of Spinal Cord Medicine, 2015 • January 1, 2015
The study investigated a combination therapy involving NRP/GRP cell transplantation, passive cycling, and chronic quipazine administration to promote recovery from complete spinal cord injury (SCI) in...
KEY FINDING: Rats receiving the combination therapy displayed an increased response to quipazine, achieving a BBB score of ≥9 starting at 8 weeks post-injury, which persisted through 12 weeks.